Okay, I need to create a detailed explanation for this MCQ about Methotrexate resistance. Let's start by understanding the core concept. Methotrexate is an antimetabolite that inhibits dihydrofolate reductase (DHFR), which is crucial for folate metabolism. Resistance can develop through various mechanisms.

The correct answer is likely related to DHFR overexpression because that's a common mechanism. When DHFR is overproduced, more enzyme is available, so the drug's inhibition isn't effective. That makes sense.

Now, the incorrect options might include things like P-glycoprotein overexpression (like with other drugs), mutations in DHFR, or maybe altered drug absorption. Let me think: P-glycoprotein is more for efflux pumps, which pump the drug out of cells, but Methotrexate isn't a substrate for that. DHFR mutations could reduce binding affinity, but overexpression is more common. Altered absorption isn't really a mechanism here since Methotrexate is given parenterally.

Clinical pearl: Remember that Methotrexate resistance in cancer or autoimmune diseases often involves DHFR overexpression. Also, using leucovorin can help by providing folinic acid to bypass the block.

Need to structure the explanation with the required sections, making sure each part is concise and within the character limit. Check for clarity and medical accuracy.

**Core Concept**
Resistance to Methotrexate, a folate antagonist, arises primarily from overexpression of **dihydrofolate reductase (DHFR)**, the enzyme it inhibits. This pharmacodynamic resistance occurs when excess DHFR compensates for the drug’s blockade of folate metabolism, reducing its therapeutic effect.

**Why the Correct Answer is Right**
Methotrexate inhibits DHFR, which is essential for converting dihydrofolate to tetrahydrofolate (a cofactor in nucleotide synthesis). In resistant cells, **DHFR overexpression** increases enzyme availability, allowing sufficient folate metabolism despite drug presence. This is a classic example of target-mediated resistance.

**Why Each Wrong Option is Incorrect**
**Option A:** *P-glycoprotein overexpression* is incorrect; Methotrexate is not a substrate for P-glycoprotein, unlike some other chemotherapeutics.
**Option B:** *Mutation in DHFR* is rare in clinical resistance but can occur in pathogens (e.g., malaria). In human cancer, overexpression—not mutation—is the dominant mechanism.
**Option C:** *Altered drug absorption* is irrelevant, as Methotrexate is administered parenterally (bypassing GI absorption).

**Clinical Pearl / High-Yield Fact**
Never forget that **DHFR overexpression** is the hallmark of Methotrexate resistance in malignancies and autoimmune disorders. For resistant cases, high-dose Methotrexate with leucovorin rescue can bypass DHFR inhibition by providing folinic acid.

**Correct Answer: C. Overexpression of dihydrofolate reductase**

✓ Correct Answer: D. Increased production of dihydrofolate reductase